Promising lead molecules identified in the Hit-to-Lead step, that had already acceptable PK properties and demonstrated hint of efficacy in-vivo, are further optimized to a preclinical candidate suitable for clinical assessment in human patients.
Lead optimisation may include evaluation of the following parameters, depending on the programme:
Some highlights of Aragen-IDD’s lead optimization infrastructure –
Digital workplace options (InCoRe platform)
InCoRe supports data sharing, compound tracking and cross-functional review across the DMTA cycle.
Data generation
In vitro and mechanistic assay data can support compound prioritisation for in vivo PK and efficacy studies.
Innovation & Expertise
Integrating wealth of scientific expertise from experienced scientists with the use of ML- & AI-generated models based on Aragen’s proprietary internal fingerprints database generated from literature and vendor databases to deliver innovative solutions.
Track record
Aragen has supported lead-optimisation programmes across multiple therapeutic areas, target classes and modalities.
Route development, Formulation expertise & Scale-up
Aragen’s Chemical development expertise together with the Formulation team provides large-scale APIs for studies in GLP or non-GLP safety assessment batches. Both chemical development and formulation team are integrated in the lead optimisation stage to identify early and robust process chemistry solutions before nomination of development candidate. Chemical development and formulation teams may support early process and formulation considerations before development candidate nomination.
